Technical ArticlesImmunohistochemical Evaluation of H-R3 a Novel Humanized Monoclonal Antibody That Neutralizes the EGF-receptorCedeño-Arias, Mercedes MSc*; Rengifo, Charles E. MD†; Batista, Yamilet Romero MSc*; Calzado, Enrique Rengifo PhD*; Rodríguez, Teresita PhD*Author Information *Center of Molecular Immunology †Manuel Fajardo General Hospital, Havana, Cuba Reprints: Enrique Rengifo, PhD, Center of Molecular Immunology, 216 St and 15 Ave, Atabey, Playa, PO Box 16040, Havana 11600, Cuba (e-mail: [email protected]). Applied Immunohistochemistry & Molecular Morphology: June 2007 - Volume 15 - Issue 2 - p 213-219 doi: 10.1097/01.pai.0000209860.82463.5f Buy Metrics Abstract The epidermal growth factor receptor (EGF-R) is an important growth regulator of epithelial cancer cells, overexpressed by several human tumors and scantly detectable in most normal tissues. The introduction of monoclonal antibodies (Mabs) and more recently engineered humanized Mabs have greatly expanded the therapeutic potential of this modality of cancer treatment. The present study was designed to compare the specificity of the murine and humanized anti-EGF-R Mabs. Biotinylated Mabs were tested in samples of fetal and adult normal and neoplastic tissues by ABC peroxidase method. All fetal tissues studied were positive for both Mabs, showing 2 different staining patterns, one homogeneous and finely granular in cytoplasm and another grosser with intense labeling in both membrane and cytoplasm. A similar recognition pattern was exhibited in adult normal tissues, where an intense reactivity was also evidenced in skin, tongue, gastrointestinal tract, renal tubules, and breast gland epithelium. In tissues from genitourinary and central nervous system, a faint staining was demonstrate, whereas those from cardiovascular and lymphoid tissues proved to be negative. These Mabs exhibited a heterogeneous and strong membrane and cytoplasm staining in neoplastic cells from lung, breast, and head and neck cancer. On the basis of these results, we conclude that the humanized (h-R3) and murine (egf/r3) anti-EGF-R Mabs show a very similar immunohistochemical pattern of recognition of fetal, adult, and neoplastic tissues. Also h-R3 Mab is a novel candidate for the development of an immunotherapeutic approach suitable for the treatment of tumors with EGF-R overexpression. © 2007 Lippincott Williams & Wilkins, Inc.